Iguratimod for the treatment of rheumatoid arthritis in Japan

Expert Review of Clinical Immunology

Volumn 11, Issue 5, 2015, Pages 565-573

  Tanaka, Keiichi ^a   Yamaguchi, Tomonobu ^a   Hara, Masako ^b  

^a TOYAMA CHEMICAL CO LTD   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

DMARD; Iguratimod; Rheumatoid arthritis; T 614

Indexed keywords

IGURATIMOD; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 17; METHOTREXATE; ANTIRHEUMATIC AGENT; CHROMONE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; SULFONAMIDE;

CHEMICAL STRUCTURE; CLINICAL EFFECTIVENESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENZYME ACTIVITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JAPAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); DRUG COMBINATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMONES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; METHOTREXATE; SULFONAMIDES;

EID: 84928174400     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1027151     Document Type: Review

References (41)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376: 1094-108
2. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19
3. Rasheed Z, Haqqi TM. Update on Targets of Biologic Therapies for Rheumatoid Arthritis. Curr Rheumatol Rev 2008;4:246
4. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11
5. Panayi G.S. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology Oxford 2005;44(Suppl 2): ii3-7
6. Benoist C, Mathis D. A revival of the B cell paradigm for rheumatoid arthritis pathogenesis? Arthritis Res 2000;2:90-4
7. Wang Q, Ma Y, Liu D, et al. The roles of B cells and their interactions with fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Int Arch Allergy Immunol 2011;155:205-11
8. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22
9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46
10. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75
11. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
12. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/ European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011;63:573-86
13. Inaba T, Tanaka K, Takeno R, et al. Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromene. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models. Chem Pharm Bull 2000;48:131-9
14. Tanaka K. Iguratimod (T-614): a novel disease modifying anti-rheumatic drug. Rheumatology Reports 2009;1:e4
15. Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc) 2012;48:577-86
16. Japan College of Rheumatology. Guidelines for the management of rheumatoid arthritis, 2014. Tokyo: Medical Review 2014; in Japanese
17. van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012;379:1712-20
18. Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824-35
19. O'Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013;369:307-18
20. Tanaka K, Makino S, Shimotori T, et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4'-1-benzopyran-4-one. 2nd communication., effect on the arachidonic acid cascades. Arzneimittelforschung 1992;42:945-50
21. Tanaka K, Kawasaki H, Kurata K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995;67: 305-14
22. Tanaka K, Aikawa Y, Kawasaki H, et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), 4th communication., Inhibitory effects on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 1992;15: 649-55
23. Kohno M, Aikawa Y, Tsubouchi Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-a induced cytokine production and nuclear factor-kB activation in cultured human synovial cells. J Rheumatol 2001;28:2591-6
24. Aikawa Y, Yamamoto M, Yamamoto T, et al. An anti-rheumatic agent T-614 inhibits NF-kB activation in LPSand TNF-a-stimulated THP-1 cells without interfering with the IkBa degradation. Inflamm Res 2002;51:188-94
25. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappaB in synovial inflammation. Curr Rherumatol Rep 2002;4:201-7
26. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008;10:212
27. Kawakami A, Tsuboi M, Urayama S, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecules, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999;133:566-74
28. Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted in SCID mice. Rheumatology Oxford 2003;42:1365-71
29. Luo Q, Sun Y, Liu W, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 2013;191:4969-78
30. rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 2007;17:1-9
31. Fries JF, Bloch DA, Sharp JT, et al. Assessment of radiologic progression in rheumatoid arthritis. Arthritis Rheum 1986;29:1-9
32. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65
33. Safety review. Available from: www. accessdata.fda.gov/drugsatfda-docs/nda/98/ 20905-ARAVA-MEDR-P2.PDF
34. Ishiguro N, Yamamoto K, Katayama K, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2013;23:430-9
35. Hara M, Ishiguro N, Katayama K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 2014;24:410-18
36. Wells G.A, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20: 557-60
37. Hara M, Abe T, Sugawara S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 2007;17:10-16
38. Okamura K, Yonemoto Y, Okura C, et al. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol 2015;25(2): 235-40
39. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Intern Med 2002;137:726-33
40. Japan College of Rheumatology. Guidelines for the treatment with methotrexate (MTX) in the management of rheumatoid arthritis, 2011. Tokyo: Yodosya 2011; in Japanese
41. Murao H, Omatsu N, Aikawa Y, et al. Iguratimod, a disease-modifying antirheumatic drug, suppressed osteoclast differentiation in vitro. In: abstract of the 2008 APLAR. Int J Rheum Dis 2008; 11(Suppl 1):A112